From: A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection
Subgroup
RR all Antibody Prophyaxis
# of Studies
# in Treatment Groups
Premature <35 weeks GA[11, 12, 15]
0.29 (0.16, 0.54)
3
624
Chronic Lung Disease (CLD)[11, 12, 15]
0.55 (0.38, 0.80)
696
Congenital Heart Disease (CHD)[11, 12, 16]
0.56 (0.40, 0.79)
865
